{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T10:28:03Z","timestamp":1789122483540,"version":"build-2803163510"},"reference-count":14,"publisher":"BMJ","issue":"1","funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2019,5,15]]},"published-print":{"date-parts":[[2019,6]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>This analysis assessed baseline predictors of remission in patients with non-radiographic axial spondyloarthritis (nr-axSpA) who received open-label adalimumab therapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>ABILITY-3 enrolled 673 adult patients with nr-axSpA who had objective evidence of inflammation by MRI or elevated high-sensitivity C reactive protein at screening, active disease and an inadequate response to two or more non-steroidal anti-inflammatory drugs. Patients received adalimumab 40 mg every other week during a 28-week open-label lead-in period. Clinical remission was defined as Ankylosing Spondylitis Disease Activity Score inactive disease (ASDAS ID; score &lt;1.3) and Assessment of SpondyloArthritis international Society partial remission (ASAS PR; score &lt;2\/10 in each of the four ASAS domains). Stepwise logistic regression was used to identify baseline predictors of remission at week 12 and at final visit (last postbaseline visit up to week 28). Only patients without missing data were included.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Overall, 593 patients were included in the ASDAS ID and 596 in the ASAS PR analysis at week 12. Younger age (\u226445 years), male sex, positive human leucocyte antigen (HLA)-B27 and higher Spondyloarthritis Research Consortium of Canada (SPARCC) MRI sacroiliac joint score were consistent predictors of remission by both ASAS ID and ASDAS PR at week 12. Results were generally similar in the final visit analysis. Other variables did not consistently predict remission.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In ABILITY-3, consistent and strong baseline predictors of remission included younger age, male sex, HLA-B27 positivity and higher SPARCC MRI sacroiliac joint score among patients with active nr-axSpA receiving adalimumab therapy, similar to previous findings in ankylosing spondylitis.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2019-000917","type":"journal-article","created":{"date-parts":[[2019,6,8]],"date-time":"2019-06-08T06:14:02Z","timestamp":1559974442000},"page":"e000917","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":38,"title":["Predictors of remission in patients with non-radiographic axial spondyloarthritis receiving open-label adalimumab in the ABILITY-3 study"],"prefix":"10.1136","volume":"5","clinical-trial-number":[{"clinical-trial-number":"nct01808118","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0285-9890","authenticated-orcid":false,"given":"Joachim","family":"Sieper","sequence":"first","affiliation":[{"name":"Department of of Gastroenterology, Infectious Diseases, and Rheumatology, Charite Universitatsmedizin Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Landew\u00e9","sequence":"additional","affiliation":[{"name":"Rheumatology & Clinical Immunology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands"},{"name":"Department of Rheumatology, Zuyderland Medical Center, Heerlen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Magrey","sequence":"additional","affiliation":[{"name":"Case Western Reserve University School of Medicine at MetroHealth Medical Center, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0893-3900","authenticated-orcid":false,"given":"Jaclyn K","family":"Anderson","sequence":"additional","affiliation":[{"name":"AbbVie Inc, North Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Zhong","sequence":"additional","affiliation":[{"name":"AbbVie Inc, North Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Wang","sequence":"additional","affiliation":[{"name":"AbbVie Inc, North Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apinya","family":"Lertratanakul","sequence":"additional","affiliation":[{"name":"AbbVie Inc, North Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,6,7]]},"reference":[{"key":"2025090313072445000_5.1.e000917.1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210770"},{"key":"2025090313072445000_5.1.e000917.2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.016386"},{"key":"2025090313072445000_5.1.e000917.3","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.073098"},{"key":"2025090313072445000_5.1.e000917.4","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.081048"},{"key":"2025090313072445000_5.1.e000917.5","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.124446"},{"key":"2025090313072445000_5.1.e000917.6","doi-asserted-by":"crossref","unstructured":"Arends S , Brouwer E , van der Veer E , et al . Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study. Arthritis Res Ther 2011;13.doi:10.1186\/ar3369","DOI":"10.1186\/ar3369"},{"key":"2025090313072445000_5.1.e000917.7","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2014-000017","article-title":"Predictors of response to TNF antagonists in patients with ankylosing spondylitis and psoriatic arthritis: systematic review and meta-analysis","volume":"1","author":"Maneiro","year":"2015","journal-title":"RMD Open"},{"key":"2025090313072445000_5.1.e000917.8","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.147744"},{"key":"2025090313072445000_5.1.e000917.9","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201766"},{"key":"2025090313072445000_5.1.e000917.10","doi-asserted-by":"crossref","unstructured":"Brown MA , Bird PA , Robinson PC , et al . Baseline MRI and CRP as predictors of response to etanercept in the management of patients with non-radiographic axial spondyloarthritis (nr-axSpA). Arthritis Rheumatol 2015;67.","DOI":"10.1136\/annrheumdis-2015-eular.2254"},{"key":"2025090313072445000_5.1.e000917.11","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1002\/art.39257","article-title":"A randomized, double-blind, placebo-controlled, sixteen-week study of subcutaneous golimumab in patients with active nonradiographic axial spondyloarthritis","volume":"67","author":"Sieper","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2025090313072445000_5.1.e000917.12","unstructured":"Humira (adalimumab) . Summary of product characteristics. Maidenhead, UK: AbbVie Ltd, 2016."},{"key":"2025090313072445000_5.1.e000917.13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31362-X"},{"key":"2025090313072445000_5.1.e000917.14","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211734"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2019-000917","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T20:07:35Z","timestamp":1756930055000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2019-000917"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":14,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,6,7]]},"published-print":{"date-parts":[[2019,6]]}},"alternative-id":["10.1136\/rmdopen-2019-000917"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2019-000917","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6]]}}}